For device companies, China is proving to be a market replete with both immediate opportunity and significant risk. Here are several examples of how large device players are attempting to navigate this challenging new environment.
China’s medical device market has been a high performer over the past 10 to 15 years, driven largely by the rapid increases in both patients’ disposable income and government insurance coverage. That combination has led to aggressive expansion in China by device multinational companies (MNCs). (See Exhibit 1.)
Exhibit 1
In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.
When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
